RGB 286638
Alternative Names: RGB-286638Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator GPC Biotech AG
- Developer Agennix AG
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Netherlands (IV)
- 12 Oct 2011 RGB 286638 is still in a phase I trial for Solid tumours in Netherlands
- 16 Nov 2010 Interim adverse events data, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR)